FIELD: chemistry.
SUBSTANCE: invention relates to the field of organic chemistry, namely to N-(3-(5-(4-chlorophenyl)-1H-pyrazolo[3,4-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propan-1-sulfonamide of formula 1 or its pharmaceutically acceptable salt. Invention also relates to a new crystalline form, an active component, a pharmaceutical composition and a drug based on compound 1.
1.
EFFECT: new compound is obtained for the prevention or treatment of proliferative diseases, characterized by BRAF kinase mutation.
10 cl, 4 dwg, 5 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BRAF KINASE INHIBITOR N-(3-(5-(4-CHLOROPHENYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-CARBONIL)-2,4-DIFLUOROPHENYL)PROPANE-1-SULFONAMIDE | 2018 |
|
RU2687107C1 |
| CRYSTAL SALTS OF B-RAF-KINASE INHIBITOR | 2018 |
|
RU2798091C2 |
| 4-OXO-3,4-DIHYDROQUINAZOLINONE COMPOUNDS FOR TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | 2021 |
|
RU2814662C1 |
| COMBINED THERAPY INCLUDING VEMURAFENIB AND INTERFERON, FOR USE IN TREATING CANCER | 2011 |
|
RU2592983C2 |
| ANTICANCER THERAPEUTIC AGENT | 2012 |
|
RU2580609C2 |
| AGENT INDUCING CELL DEATH FOR CELLS HAVING BRAF GENE MUTATIONS, AGENT SUPPRESSING GROWTH OF SUCH CELLS, AND PHARMACEUTICAL COMPOSITION FOR THE THERAPY OF DISEASES CAUSED BY GROWTH DEFECT OF SUCH CELLS | 2016 |
|
RU2760835C2 |
| QUINAZOLIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | 2020 |
|
RU2797606C1 |
| MKK4 PROTEIN KINASE INHIBITORS FOR STIMULATION OF LIVER REGENERATION OR REDUCTION OR PREVENTION OF HEPATOCYTE DEATH | 2019 |
|
RU2788000C2 |
| COMBINED ANTICANCER THERAPY | 2011 |
|
RU2607596C2 |
| NEW PAN-RAF KINASE INHIBITOR AND APPLICATIONS THEREOF | 2019 |
|
RU2792626C1 |
